Mechanisms of Resistance to TKI in NSCLC
D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses mechanisms of resistance to TKIs in oncogene-driven non–small cell lung cancer.
D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses mechanisms of resistance to TKIs in oncogene-driven nonsmall cell lung cancer (NSCLC).
Even though osimertinib (Tagrisso) is better in the brain than the other agents in this class, it is not a perfect central nervous system (CNS) drug, Camidge says. It is marketed as a CNS penetrant, but patients still progress on osimertinib. Researchers have to decide if this is a dosing situation with osimertinib or if there are simply better drugs in the future. Studies have looked at adding erlotinib (Tarceva) and gefitinib (Iressa) to treatment, but Camidge notes this works in a petri dish but not in a patient.
Some mechanisms of resistance are understood by thoracic oncologists. For example, some patients withEGFR
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
